Home / Business and Economy / Novo Nordisk Sues Hims & Hers Over Wegovy Knockoff
Novo Nordisk Sues Hims & Hers Over Wegovy Knockoff
5 Feb
Summary
- Novo Nordisk is suing Hims & Hers for offering compounded Wegovy copies.
- Hims & Hers plans to offer a compounded version for $49 monthly.
- Novo Nordisk cites patient safety and intellectual property risks.
Novo Nordisk is initiating legal proceedings against Hims & Hers, an online telehealth provider. This action follows Hims & Hers' announcement that it will offer a compounded version of the popular Wegovy pill.
Hims & Hers intends to market this compounded drug at an introductory price of $49 per month. Novo Nordisk has strongly condemned this move, labeling it as "illegal mass compounding" that poses serious threats to patient safety. The company has vowed to pursue legal and regulatory measures.
Novo Nordisk emphasized its role as the sole manufacturer of the FDA-approved oral Wegovy, formulated with proprietary SNAC technology to enhance semaglutide absorption. The company aims to safeguard patients, its intellectual property, and the established drug approval system.
